drugset / Trial / NCT05411146

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

NCT05411146

Phase 1 Completed 8 enrolled Arcus Biosciences, Inc. Gilead Sciences · collab
NaSingle-groupOpen-labelBasic science

Summary

This study will assess absorption, metabolism, and excretion of Radioactively Labeled Etrumadenant in healthy volunteers.

Timeline

Start
2022-05-25
Primary completion
2022-07-07
Completion
2022-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Etrumadenant Small molecule Oral

Indications

No indication recorded.